Scholarlink

<p>Type 1 diabetes is associated with excess cardiovascular risk, even after accounting&#xa0;for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document&#xa0;the metabolic abnormalities that contribute to&#xa0;the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes&#xa0;medications&#xa0;prevent premature morbidity and mortality in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Use of Cardioprotective Adjuncts in Type 1 Diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月6日

查看全文
  • Jerry R. Greenfield,
  • Ruth Frampton,
  • Kellie Millard,
  • Jennifer R. Snaith

摘要

Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.